Pharmacological targeting of osteoblasts or the balance between osteoblasts and osteoclasts is already an accepted strategy for the treatment of osteoporosis, and the FDA-approved osteoporosis drugs target RANKL, parathyroid hormone, and sclerostin [20]. The gene discussed is TNFSF11; the disease is osteoporosis.